


CLAIMS

We claim:

1. A compound of Formula I



Formula I

wherein

R is selected from the group consisting of OH, N₃, -OR₁, -O-aryl, -O-heteroaryl, -OSO₂R₂, -NR₃R₄, and



wherein

- (i) R₁ is benzyl or C₂₋₆-acyl;
- (ii) R₂ is selected from the group consisting of phenyl, tolyl, and C₁₋₆-alkyl; and
- (iii) R₃ and R₄ are independently selected from the group consisting of hydrogen, C₃₋₆-cycloalkyl, phenyl, tert-butoxycarbonyl, fluorenyloxycarbonyl, benzyloxycarbonyl, -CO₂-R₅, -CO-R₅, -CO-SR₅, -CS-R₅, P(O)(OR₆)(OR₇), -SO₂-R₈ and C₁₋₆-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of C₁₋₅-alkoxycarbonyl, OH, cyano, and halogen, wherein

R₅ is selected from the group consisting of hydrogen, C₃₋₆-cycloalkyl, trifluoromethyl, phenyl, benzyl, and C₁₋₆-alkyl optionally substituted with 1 to 3 members independently selected from the group consisting of C₁₋₅-alkoxycarbonyl, OH, cyano, halogen, and -NR₉R₁₀ in which R₉ and R₁₀ are independently selected from the group consisting of hydrogen, phenyl and C₁₋₄-alkyl;

R_6 and R_7 are independently hydrogen or C_{1-4} -alkyl; and

R_8 is phenyl or C_{1-4} -alkyl;


R_{11} is selected from the group consisting of hydrogen, alkyl, $-OR_{13}$, $-SR_{13}$, amino, $-NR_{13}R_{14}$, aryl(C_{1-8})alkyl, and mono-, di-, tri-, or per-halo C_{1-8} -alkyl;

R_{12} is selected from the group consisting of CN, $-COR_{13}$, $-COOR_{13}$, $-CO-NR_{13}R_{14}$, $-SO_2R_{13}$, $-SO_2-NR_{13}R_{14}$, and nitro; and

R_{13} and R_{14} are independently selected from the group consisting of hydrogen, alkyl, and aryl, or R_{13} and R_{14} taken together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group;

X is 0 to 4 members independently selected from the group consisting of halogen, OH, mercapto, nitro, halo- C_{1-8} -alkyl, C_{1-8} -alkoxy, C_{1-8} -alkylthio, C_{1-8} -alkyl-amino, di(C_{1-8} -alkyl)amino, formyl, carboxy, alkoxycarbonyl, C_{1-8} alkyl-CO-O-, C_{1-8} alkyl-CO-NH-, carboxamide, aryl, heteroaryl, CN, amino, C_{3-6} -cycloalkyl, C_{1-8} -alkyl optionally substituted with one or more members selected from the group consisting of F, Cl, OH, C_{1-8} alkoxy and C_{1-8} acyloxy; and

Y is a radical of Formula II:



Formula II

wherein

R_{15} , R_{16} , R_{17} , R_{18} , R_{19} , and R_{20} are each independently selected from the group consisting of hydrogen, CN, nitro, C_{1-8} -alkyl, halo- C_{1-8} -alkyl, formyl, carboxy,

alkoxycarbonyl, carboxamide, aryl, and heteroaryl, or R_{15} and R_{16} and/or R_{17} and R_{18} and/or R_{19} and R_{20} together form an oxo group;


the moiety W represents any five- to ten-membered aromatic or heteroaromatic ring, said heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N;

Z is selected from the group consisting of hydrogen, halogen, amino, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, CN, CHO, alkyl-CO-, alkoxy, (C₁₋₈-alkyl)-CONH-, and $R_{21}R_{22}N$ -alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C₁₋₆-alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group; and

m is 0 or 1

and the pharmaceutically acceptable salts and esters thereof.

2. The compound of claim 1 wherein X is halogen.
3. The compound of claim 1 wherein Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.
4. The compound of claim 1 wherein the moiety W is a fused phenyl ring or a five- or six-membered heteroaromatic ring having 1 to 4 members selected from the group consisting of S, O, and N.
5. The compound of claim 1 wherein Y is selected from the group consisting of




wherein

- 5 Z is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, alkyl-CO-, and $R_{21}R_{22}N$ -alkyl- wherein R_{21} and R_{22} are independently selected from the group consisting of hydrogen, C_{1-6} -alkyl, benzyl, aryl, and heteroaryl, or R_{21} and R_{22} together with the nitrogen atom to which they are attached form an unsubstituted or substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, or piperazinyl group.


6. The compound of claim 5 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.

7. The compound of claim 1 wherein R is selected from the group consisting of




8. The compound of claim 6 wherein X is halogen and Z is selected from the group consisting of hydrogen, alkyl, aryl, and heteroaryl.


9. A compound of Claim 1 having the formula:



10. A compound of Claim 1 having the formula:




11. A compound of Claim 1 having the formula:




5


12. A compound of Claim 1 having the formula:




13. A compound of Claim 1 having the formula:




10 14. A compound of Claim 1 having the formula:




15. A compound of Claim 1 having the formula:



16. A compound of Claim 1 having the formula:



17. A compound of Claim 1 having the formula:



18. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

19. A method of treating a subject having a condition caused by or contributed to by bacterial infection, which comprises administering to said mammal a therapeutically effective amount of the compound according to Claim 1.

20. A method of preventing a subject from suffering from a condition caused by or contributed to by bacterial infection, which comprises administering to the subject a prophylactically effective dose of the pharmaceutical composition of a compound according to Claim 1.

21. The method of Claim 19 or 20 wherein said condition is selected from the group consisting of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, bone and joint infections and hospital-acquired lung infections.

22. The method of Claim 19 or 20 wherein said bacterium is selected from the group consisting of *S. aureus*, *S. epidermidis*, *S. pneumoniae*, *S. pyogenes*, *Enterococcus spp.*, *Moraxella catarrhalis* and *H. influenzae*.

23. The method of Claim 19 or 20 wherein said bacterium is a Gram-positive coccus.

24. The method of Claim 23 wherein said Gram-positive coccus is drug-resistant.

5

20090201 1527001